Should We Increase GFR with Bardoxolone in Alport Syndrome?
Author:
Publisher
American Society of Nephrology (ASN)
Subject
Nephrology,General Medicine
Reference9 articles.
1. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease
2. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
3. Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
4. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
5. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. NRF2 in kidney physiology and disease;Physiological Reports;2024-02-28
2. Finerenone and other future therapeutic options for Alport syndrome;Journal of Rare Diseases;2023-11-08
3. NRF2 Deficiency Attenuates Diabetic Kidney Disease in Db/Db Mice via Down-Regulation of Angiotensinogen, SGLT2, CD36, and FABP4 Expression and Lipid Accumulation in Renal Proximal Tubular Cells;Antioxidants;2023-09-04
4. Alport Syndrome: Clinical Spectrum and Therapeutic Advances;Kidney Medicine;2023-05
5. Hydroxychloroquine Ameliorates Hematuria in Children with X-Linked Alport Syndrome: Retrospective Case Series Study;Pharmacogenomics and Personalized Medicine;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3